ទំព័រដើម › មហារីកតូច › តេនណេស៊ី › Nashville
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកតូច នៅក្នុង Nashville, TN
ការសិក្សាចំនួន 43 សម្រាប់ មហារីកតូច កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Nashville (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- GSK Investigational Site, Nashville
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Urology Associates, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
កំពុងជ្រើសរើសដំណាក់កាល 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Research Site, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- និង 7 ទៀត
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
កំពុងជ្រើសរើសដំណាក់កាល 2
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
កំពុងជ្រើសរើសដំណាក់កាល 3
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
កំពុងជ្រើសរើសដំណាក់កាល 3
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Tennessee Oncology Nashville, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- SCRI Oncology Partners, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- United States Oncology Regulatory Affairs Corporate Office, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Henry-Joyce Cancer Clinic, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Tennessee Oncology PLLC, Nashville
PSMA PET Combined With MRI for the Detection of PCa
កំពុងជ្រើសរើសដំណាក់កាល 3ស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Urology Associates of Nashville, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Investigative Site #102, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
កំពុងជ្រើសរើសដំណាក់កាល 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- SCRI Oncology Partners, Nashville
ការសាកល្បងសម្រាប់ មហារីកតូច នៅក្នុងទីក្រុងផ្សេងទៀត
- New York City, NYការសិក្សា 103
- Houston, TXការសិក្សា 76
- Los Angeles, CAការសិក្សា 61
- Boston, MAការសិក្សា 59
- St. Louis, MOការសិក្សា 46
- Chicago, ILការសិក្សា 45
- San Francisco, CAការសិក្សា 45
- Philadelphia, PAការសិក្សា 44
- Baltimore, MDការសិក្សា 43
- Seattle, WAការសិក្សា 42
- Washington, DCការសិក្សា 38
- Dallas, TXការសិក្សា 36
ការសិក្សាផ្សេងទៀតនៅក្នុង Nashville
- Non-Small Cell Lung Cancerការសិក្សា 97
- មហារីកទ្រូងការសិក្សា 81
- មហារីកដែលរីករាលដាលការសិក្សា 70
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 69
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 65
- មហារីកស៊ុតការសិក្សា 49
- មហារីកសួតការសិក្សា 40
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 39
- មហារីកតំបក់ការសិក្សា 39
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 38
- មេឡាណូម៉ាការសិក្សា 33
- ជំងឺ Multiple Myelomaការសិក្សា 32
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។